Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083908 | 1.00 | ATM (0.34) | ATMMEN1TSHRHTTKMT2A | |
| SCHEMBL7677570 | 1.00 | ATM (0.34) | ATMMEN1TSHRHTTKMT2A | |
| SCHEMBL7677574 | 1.00 | ATM (0.34) | ATMMEN1TSHRHTTKMT2A | |
| Butane SCHEMBL7678465 | 0.96 | MEN1 (0.33) | ATMMEN1TSHRHTTKMT2A | |
| SCHEMBL26119442 | 0.87 | DNMT1 (0.34) | DNMT1 | |
| SCHEMBL20629796 | 0.87 | CHRM2 (0.32) | MEN1TSHRHTTKMT2ACHRM2 | |
| SCHEMBL26115363 | 0.87 | DNMT1 (0.34) | DNMT1 | |
| SCHEMBL18771738 | 0.87 | CHRM2 (0.32) | MEN1TSHRHTTKMT2ACHRM2 | |
| SCHEMBL18771733 | 0.87 | CHRM2 (0.32) | MEN1TSHRHTTKMT2ACHRM2 | |
| SCHEMBL14339361 | 0.81 | ATM (0.40) | ATMMEN1TSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-6350882-B1 | REACTION OF PROLINE SALT AND ALKALI HALIDE WITH UNSATURATED ALDEHYDE, MIXING, ACIDIFICATION AND BASIFICATION | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885MEN1 1465/4885TSHR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.